- Home
- Publications
- Publication Search
- Publication Details
Title
Endometrial cancer: redefining the molecular-targeted approach
Authors
Keywords
Cancer, Endometrium, Endometrial cancer, Chemotherapy, Targeted therapy, Molecular targets
Journal
CANCER CHEMOTHERAPY AND PHARMACOLOGY
Volume 76, Issue 1, Pages 1-11
Publisher
Springer Nature
Online
2015-05-02
DOI
10.1007/s00280-015-2758-z
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Translating Mismatch Repair Mechanism into Cancer Care
- (2014) Christopher Heinen CURRENT DRUG TARGETS
- Neratinib shows efficacy in the treatment of HER2/neu amplified uterine serous carcinoma in vitro and in vivo
- (2014) Carlton L. Schwab et al. GYNECOLOGIC ONCOLOGY
- Phase II study of oral ridaforolimus in women with recurrent or metastatic endometrial cancer
- (2014) Daliah Tsoref et al. GYNECOLOGIC ONCOLOGY
- A phase II trial of sunitinib in women with metastatic or recurrent endometrial carcinoma: A study of the Princess Margaret, Chicago and California Consortia
- (2014) Vincent Castonguay et al. GYNECOLOGIC ONCOLOGY
- A phase II evaluation of nintedanib (BIBF-1120) in the treatment of recurrent or persistent endometrial cancer: An NRG Oncology/Gynecologic Oncology Group Study
- (2014) Don S. Dizon et al. GYNECOLOGIC ONCOLOGY
- A phase II trial of brivanib in recurrent or persistent endometrial cancer: An NRG Oncology/Gynecologic Oncology Group Study
- (2014) Matthew A. Powell et al. GYNECOLOGIC ONCOLOGY
- Temsirolimus with or without megestrol acetate and tamoxifen for endometrial cancer: A gynecologic oncology group study
- (2014) Gini F. Fleming et al. GYNECOLOGIC ONCOLOGY
- Temsirolimus and pegylated liposomal doxorubicin (PLD) combination therapy in breast, endometrial, and ovarian cancer: phase Ib results and prediction of clinical outcome with FDG-PET/CT
- (2014) Marye J. Boers-Sonderen et al. Targeted Oncology
- Molecular Alterations of PI3K/Akt/mTOR Pathway: A Therapeutic Target in Endometrial Cancer
- (2014) Athanasia Pavlidou et al. TheScientificWorldJOURNAL
- Combined targeting of FGFR2 and mTOR by ponatinib and ridaforolimus results in synergistic antitumor activity in FGFR2 mutant endometrial cancer models
- (2013) Joseph M. Gozgit et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Clinical and toxicity predictors of response and progression to temsirolimus in women with recurrent or metastatic endometrial cancer
- (2013) Rachel A. Goodwin et al. GYNECOLOGIC ONCOLOGY
- Metformin is associated with improved survival in endometrial cancer
- (2013) Emily M. Ko et al. GYNECOLOGIC ONCOLOGY
- Activity of the Fibroblast Growth Factor Receptor Inhibitors Dovitinib (TKI258) and NVP-BGJ398 in Human Endometrial Cancer Cells
- (2013) G. E. Konecny et al. MOLECULAR CANCER THERAPEUTICS
- Integrated genomic characterization of endometrial carcinoma
- (2013) Gad Getz et al. NATURE
- A phase II evaluation of aflibercept in the treatment of recurrent or persistent endometrial cancer: A Gynecologic Oncology Group study
- (2012) Robert L. Coleman et al. GYNECOLOGIC ONCOLOGY
- Lapatinib and potential prognostic value of EGFR mutations in a Gynecologic Oncology Group phase II trial of persistent or recurrent endometrial cancer
- (2012) Kimberly K. Leslie et al. GYNECOLOGIC ONCOLOGY
- Late-Breaking Abstract 1: Randomized phase III noninferiority trial of first line chemotherapy for metastatic or recurrent endometrial carcinoma: A Gynecologic Oncology Group study
- (2012) D. Miller et al. GYNECOLOGIC ONCOLOGY
- Phase II trial of combination bevacizumab and temsirolimus in the treatment of recurrent or persistent endometrial carcinoma: A Gynecologic Oncology Group study
- (2012) Edwin A. Alvarez et al. GYNECOLOGIC ONCOLOGY
- PIK3R1 (p85 ) Is Somatically Mutated at High Frequency in Primary Endometrial Cancer
- (2011) M. E. Urick et al. CANCER RESEARCH
- Phase II Trial of Bevacizumab in Recurrent or Persistent Endometrial Cancer: A Gynecologic Oncology Group Study
- (2011) Carol Aghajanian et al. JOURNAL OF CLINICAL ONCOLOGY
- FGFR2 alterations in endometrial carcinoma
- (2011) Sonia Gatius et al. MODERN PATHOLOGY
- GDC-0980 Is a Novel Class I PI3K/mTOR Kinase Inhibitor with Robust Activity in Cancer Models Driven by the PI3K Pathway
- (2011) J. J. Wallin et al. MOLECULAR CANCER THERAPEUTICS
- High Frequency of PIK3R1 and PIK3R2 Mutations in Endometrial Cancer Elucidates a Novel Mechanism for Regulation of PTEN Protein Stability
- (2011) Lydia W.T. Cheung et al. Cancer Discovery
- Metformin and rapamycin have distinct effects on the AKT pathway and proliferation in breast cancer cells
- (2010) Mahvash Zakikhani et al. BREAST CANCER RESEARCH AND TREATMENT
- A phase 2 study of the oral mammalian target of rapamycin inhibitor, everolimus, in patients with recurrent endometrial carcinoma
- (2010) Brian M. Slomovitz et al. CANCER
- Serum tumour markers in gynaecological cancers
- (2010) Pakhee Aggarwal et al. MATURITAS
- The oncogenic mutation in the pleckstrin homology domain of AKT1 in endometrial carcinomas
- (2009) K Shoji et al. BRITISH JOURNAL OF CANCER
- In vitro activity of pertuzumab in combination with trastuzumab in uterine serous papillary adenocarcinoma
- (2009) K El-Sahwi et al. BRITISH JOURNAL OF CANCER
- Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: A Gynecologic Oncology Group study
- (2009) Gini F. Fleming et al. GYNECOLOGIC ONCOLOGY
- Inhibition of Activated Fibroblast Growth Factor Receptor 2 in Endometrial Cancer Cells Induces Cell Death Despite PTEN Abrogation
- (2008) S. A. Byron et al. CANCER RESEARCH
- Trastuzumab treatment in patients with advanced or recurrent endometrial carcinoma overexpressing HER2/neu
- (2008) Alessandro D. Santin et al. INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS
- Phase II Study of Erlotinib in Recurrent or Metastatic Endometrial Cancer: NCIC IND-148
- (2008) Amit M. Oza et al. JOURNAL OF CLINICAL ONCOLOGY
- Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity
- (2008) S.-M. Maira et al. MOLECULAR CANCER THERAPEUTICS
- Drug-sensitive FGFR2 mutations in endometrial carcinoma
- (2008) A. Dutt et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Novel molecular profiles of endometrial cancer—new light through old windows
- (2007) A. Doll et al. JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started